Skip to main content
Premium Trial:

Request an Annual Quote

JumpCode Genomics Raises $21M in Series B Financing Round

NEW YORK – Jumpcode Genomics said on Tuesday that it has raised $21 million in a Series B financing round.

The funding round was co-led by Baird Capital and Arboretum Ventures, and included existing investor LYZZ Capital.

The company, which was founded in 2016, is using the financing to accelerate the commercialization of its CRISPRclean technology, expand into additional markets, and further build its team. JumpCode emerged from stealth mode in 2020 with the CRISPR-based technology, which aims to turn down the background noise in next-generation sequencing libraries by depleting unwanted nucleic acid sequences from NGS libraries and leaving behind only targets of interest.

"Since emerging from stealth mode in late 2020, we've received robust interest in Jumpcode from the life sciences community," JumpCode CEO Yaron Hakak said in a statement. "Our CRISPRclean technology has helped scientists at renowned medical centers, academic, and biotechnology organizations address research bottlenecks by depleting unwanted nucleic acid molecules from sequencing libraries, enabling them to see what they previously could not."

The company also announced it has appointed Ampersand Capital Partners Operating Partner Frank Witney to its board. Witney previously served as CEO of Affymetrix and CEO of Dionex, and has held senior executive positions at PerkinElmer, Packard BioScience, and Bio-Rad Laboratories.